New CAR-T therapy trial offers hope for patients with aggressive lymphoma
NCT ID NCT07473167
Summary
This study is testing a new CAR-T cell therapy called TC011 for adults with aggressive B-cell lymphoma that has come back or hasn't responded to at least two prior treatments. The main goals are to find a safe dose and see if the therapy can shrink or eliminate tumors. It is for patients whose cancer is no longer controlled by standard chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, Seoul, 03080, South Korea
Contact
Conditions
Explore the condition pages connected to this study.